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Cultivated cure,  
regenerated affliction  
Encounters with ALS and stem cell regeneration in India 
Aditya Bharadwaj 
Abstract 
In this think piece, I interrogate the notion of cure in order to address the idea of disease. 
My intention is to show how emerging biotechnological modalities that cultivate an idea of 
‘cure as regeneration’ dislocate expert knowledge, descriptions of disease, and its 
representation into contested new terrains. In approaching disease from the vantage point of 
the ‘cultivated cure’ I seek to trouble our commonsense view of afflictions. Drawing on 
ethnographic data from a longitudinal project engaged in mapping stem cell technologies in 
India, I conceptualize how ‘cure as regeneration’ reanimates the figures of disease and 
medical knowledge. I take up Veena Das’s challenging query: is it necessary to define terms – 
illness, disease, diagnosis, health – that defy neat characterization?  
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Diseases are new ways of life. 
– Georges Canguilhem, The Normal and the Pathological 
Introduction  
Veena Das (2015) encourages scholars to view everyday life as a site for cultivating cures for 
gestating afflictions. This think piece is inspired by her pertinent query: ‘Is it necessary to 
define those terms – illness, disease, diagnosis, health – through which we intuitively come 
to know the disturbances in our world but that defy any neat characterizations’ (Das 2015, 
212)? As she rightly argues, the issue at stake is not merely that of discerning meaning but 
also of ‘trying to understand what the being of this entity (illness, disease) is that seems to 
have such a restless relation to one’s own experience and such a need to find authorization 
of “its” reality’ (Das 2015, 213). Das’s ethnography skirts around a preoccupation with 
categorical clarity and instead arrives at a range of questions that arise in relation to the 
shifting lines of illness and health in low-income neighbourhoods. I wish to suggest that the 
chronic and progressively pathological affliction may be a site for witnessing the anatomy of 
a cultured and cultivated cure from within the emergent field of regenerative medicine. A 
cure is ‘cultivated’ in the sense that it is the enmeshment of: 1) the constant refinement of 
interventions tailored to a patient, 2) the culturing and tending to stem cells as a therapeutic 
agent, and 3) the ways in which the patient responds to disease through a work on him or 
herself. How might we see a progressive and aggressive affliction as paradoxically 
regenerative, in the face of curative operations that end up maintaining a tenuous truce, a 
dormant zone, that can be imagined as health? This fleeting ‘health’, wedged precariously 
between a cultivated cure and a regenerating affliction, offers fascinating insights into the 
emerging world of stem cell therapeutics.  
But what is a cure? It is, I argue, the restoration of a dormant state. To cure is to cultivate 
and return (the body) to a normative state of dormancy known as ‘health’. It is a dormant 
space where illness is forgotten and paradoxically cultivated for further curative operations. 
It is a deep sleep in which illness is a bad dream. An affliction in this respect is an awakening 
from a dormant state. A chronic affliction can be likened to uninterrupted wakefulness, a 
state of chronic sleep deprivation. This wakefulness (re)activates the dormant circuit of pain 
and suffering.  
Disease, as Georges Canguilhem (1998, 40–41) reminds us, is a generalized reaction designed 
to bring about a cure; the organism develops a disease to get well. This struggle in the 
‘natural’ order creates conditions for tolerating infractions of established norms, and for 
establishing new norms under new conditions scripted by afflictions. In other words, 
afflictions rouse pathology to life and life to a state of pathology. In this respect a cultivated 






cure is a struggle to normalize pathology to a point of dormancy. I visualize the notion of 
dormancy as the two faces of Janus: dormancy is both ‘health’ and silent affliction. These 
operations seldom re-establish the norm but instead merely ‘cure’ pathology to the point of 
establishing a new normal (Canguilhem 1998). The notion of cure in this respect is also 
doubly articulate. It relieves or resolves an affliction – its cause, symptom, chronic 
manifestation – or it preserves or hardens (like cured food or substance) a state of pathology. 
In each instance a cured affliction is cultivated and prone to mutation. In the dormant state, 
moments when seemingly nothing happens, destinies of pathologies and their intended cures 
are relentlessly cultured and shaped. A state of dormancy, or ‘health’ in this respect, is a 
mirage; following Canguilhem (1998) one can argue that an affliction can ‘play its tricks’ at 
the subterranean (tissue) level: (undetected) sickness can exist without a sick person.  
The foregoing is the theoretical plotline underscoring the culture and cultivation of emerging 
embryonic stem cell cures for some of the worst known chronic and progressive afflictions. 
In this essay I take the therapeutic journey of an amyotrophic lateral sclerosis (ALS) patient 
as a route into the undulating typography of afflictions and human embryonic stem cell 
‘cures’. I am not attempting to explain away the anatomy of an affliction via glib definitional 
fiat but rather taking a tentative step into ‘ethnographic reality’, co-conjured with the 
afflicted, to decipher how zones of dormancy and the affliction’s eventual activation produce 
shifting manifestations and meanings of disease and health that often defy being captured by 
language.  
Material and methods  
The ethnographic focus is a small clinical facility in New Delhi. Since 2002, I have followed 
the culture, cultivation, and clinical application of human embryonic stem cells (hESC) at 
this facility. The clinic is a small player in the high-stakes world of regenerative medicine. It 
is seen as a rank outlier and is often criticized for having moved too quickly ‘from bench to 
bedside’ without passing certain critical scientific milestones that have become accepted as 
the gold standard within the Euro-American landscape of science and biomedicine. I have 
described the politics of name-calling and ‘subalternity’ involving the clinic and how the 
clinic has addressed these long-standing criticisms elsewhere (Bharadwaj 2015); here I delve 
into one longitudinal conversation with an ALS patient I have been following since 2013. 
The larger research project in which this think piece is embedded examines the emergence of 
stem cell technologies within the scientific, ethical, and regulatory landscapes in India 
(European Research Council, grant number 313769). Interactions with the growing number 
of Indians and foreigners seeking treatment shed light on the contingent nature of healing 
and agency, and the wider reaction to hESC-based therapies. 






Methodologically I grapple with the question of whether ethnography is meant to illustrate a 
theoretical argument or whether theory might be built into ethnography itself (Das 2015, 15). 
I hope that as the reader’s immersion in the life of the ALS-afflicted patient featured in this 
think piece deepens, theory will begin to embed itself in the structure of a life rattled and 
threatened. The conversation I report is not so much in pursuit of building a theodicy, to 
make sense of an afflicted life, but rather to reclaim a contracting zone of health in the face 
of a rousing affliction. 
‘Cured’ affliction 
ALS is a form of motor neuron disease. It attacks the nerve cells responsible for voluntary 
muscle actions, leading to the progressive weakening of muscles and eventual death. ALS 
can be inherited (in 10 percent of cases) or manifest randomly. The causes can range from 
genetic mutation to an imbalance of the chemical messenger glutamate to an autoimmune 
response that can cause the immune system to attack functioning nerve cells and protein 
accumulation within nerve cells, resulting in nerve-cell death. The prevalence of ALS in the 
United States is 32 per 100,000; because most epidemiological research on ALS is confined 
to the United States and Europe, it is at present difficult to provide global incidence and 
prevalence rates (Chió et al. 2013). At present no known and credible ‘cure’ for ALS exists. 
The drug riluzole is the only approved treatment believed to slow progression of the disease, 
and it is usually prescribed from the point of diagnosis. However, even in the best-case 
scenario, riluzole can help control some symptoms and extend one’s life only by three 
months. At $2,035 per month, the drug is extremely expensive. 
Recently ALS attracted global attention through the Ice Bucket Challenge, a campaign to 
raise awareness of the disease by encouraging people to videotape themselves pouring a 
bucket of ice water over their heads, and to challenge acquaintances and friends to do the 
same, with some participants donating to ALS research. However, despite the growing 
awareness of ALS around the globe, the condition is relatively unknown in India. It is 
therefore no surprise that my only encounters with the condition occurred in the context of 
hESC treatments at the New Delhi facility, where globally mobile treatment seekers, on their 
peripatetic quest for hESC ‘cultivated cures’, routinely came.  
I met Warner (pseudonym) in New Delhi when he first visited the clinic director’s 
consultation room in May 2013. He was trembling, and his hands and arms were shaking 
with rapid fasciculations. The quivering skin and spasmodic activity were unremitting, and 
his speech was slow and frequently inaudible. Warner had been diagnosed with ALS in early 
2013 and given fewer than three months to live. A qualified surgeon who understood 
biomedical prognoses, he looked for alternatives to fight the disease’s rapid progression. 






One of his colleagues in Germany, who had seen some of his patients undergo successful 
stem cell treatments in the New Delhi clinical facility, suggested he try hESC treatment.  
Warner had led an active life and had been a formidable athlete, running a full marathon in 
2005 and several half marathons until 2009, when he noticed muscular fasciculations 
inexorably rising from his legs to the rest of his body and down his arms. He consulted 
eminent doctors, including professors of medicine (some of whom were his colleagues), and 
was put on hormonal therapy involving cortisone. Magnesium and calcium prescriptions 
quickly followed. However, his body continued to tremble. He underwent a battery of tests, 
including an electromyogram conduction test, and nothing untoward was discovered. 
Similarly, no antibodies were discovered, and the specialist surmised it could not be ALS but 
only benign muscular fasciculations and cramps. Warner researched his condition on the 
internet extensively but still couldn’t piece together the mysterious symptoms that 
inexplicably waxed and waned. He soon readjusted to ‘a new normal’ and began to shape his 
life around this constant annoyance. However, when he returned to his active life and 
running, the cramps became more persistent. By the middle of 2012, his strength had rapidly 
deteriorated, and he was unable to lift his foot.  
In mid-2012, however, Warner continued to push himself in the face of his deteriorating 
condition. He noticed the changes but could do nothing except moderate his running 
around his fatigue. He could only run seven to ten kilometres, a daunting task for a 
physically ‘fit’ person, but a huge setback for an enthusiastic long-distance runner. To make 
matters worse, his breathing had rapidly deteriorated and become laboured. In October 
2012, his cramps became so severe he could not sleep at night. Desperate to find a 
resolution, he began to reach out to specialists for an expert referral but received only a 
prescription for sleeping pills.  
By 2013 Warner’s muscles had significantly weakened, and he began to lose weight. Despite 
increasing his calorie intake, his weight and muscle strength were in free fall. In May 2013 he 
consulted a top neurologist at one of Berlin’s leading hospitals and was devastated to receive 
a firm diagnosis of chronic ALS. He was told that his ALS was so serious ‘it must be carried 
on the shoulders of many doctors’. Second and third opinions only corroborated the 
diagnosis of  ‘motor neuron disease sub-form ALS, sub-form peripheral muscle atrophy’.  
It was as if the horrific affliction that had lain undetected deep within Warner’s folding tissue 
while ‘healthy’ Warner ran marathons had suddenly roused from its dormant slumber to 
regenerate itself as pathology demanding a cultivated cure. The destinies of cures and 
afflictions are inextricably linked. Even in the best-case scenario, where an affliction is 
pushed back into a state of hibernation, normality and ‘health’ reappear truncated. In 






Warner’s case, it was clear his strength could only return by putting the affliction to sleep. 
The cultivated cure he had embraced above other cures (such as riluzole, occasionally 
extending life by three months) could work to either return the advancing ALS to a state of 
dormancy or ‘cure’ or ‘harden’ it still further.  
Warner is a general surgeon but has a fair amount of neurology in his training and surgical 
experience. He understood exactly what he was up against and was networking relentlessly to 
figure out an ‘alternative’ to mainstream cures that paradoxically only ‘hardened’ the 
affliction. It was through the course of actively researching an alternative that a colleague 
mentioned a doctor in Bavaria, who had patients return from India after hESC treatments. 
However, the process of establishing contact with the doctor was not easy: their phone calls 
remained unanswered, and automated messages announced the clinic wasn’t accepting new 
patients. It was as if Warner’s life had suddenly hit the ‘complication’ stage in the Labovian 
narrative structure (Labov 1972). The persistent Warner, however, sent urgent emails and 
heard from the doctor eventually. After running several baseline tests, she concluded that 
hESC treatment in India was their only option.  
Warner arrived in New Delhi looking forward to the treatment. Unlike many other Germans 
and Americans I had spoken to, he displayed no dismay or culture shock upon arrival but 
only reiterated his wish to get his life back, a ‘healthy’ life contained in a web of kinship and 
bonds of affect. In this tightly knit unit, his wife, daughter, and in-laws featured prominently, 
people who loved him and cared for him. Warner’s wife and her father, with whom he had a 
strong bond, accompanied him on the trip. Warner was steadfast in his resolve to fight the 
advancing ALS and had prepared himself for the eventuality that, if his pursuit of a cure 
failed, he would not be afraid of his end. He often remarked to me and his wife that he knew 
how people with life-threatening diseases coped and that he had, in consultation with his 
wife and supportive family, come to the decision he would do everything in his power to 
resist a future that would reduce him to an entity strapped to a ventilator. If the treatment 
failed, their plan was to go to Switzerland to bring his struggle to a peaceful end via assisted 
suicide. 
Warner was finally ensconced in his small room at the clinic and began looking forward to 
the stem cell insertions. ‘I have no idea what to expect’, he said, a frequent statement of his. 
Warner firmly believed he had nothing to lose. He was looking for incremental progress, and 
his first priority was to stabilize his breathing. Warner didn’t have much time to relax and 
adjust to his new environment, however, as he was almost immediately put through a series 
of diagnostic tests and exams. He felt utterly exhausted as the clinicians swung into action. 
The clinic had treated ALS patients, and the clinical director and her team were accustomed 
to treating patients who were in the late stages of disease and seeking hESC therapy as a last 
resort. Judging by ALS standards Warner was a difficult case; the clinical team had not seen 






such a complicated one before. His intimate understanding of how aggressively ALS 
progressed helped. Although the pace of tests and protocols left him feeling utterly 
exhausted and ‘smashed’, from a clinical point of view there was no time to waste due to his 
rapidly worsening condition, and the team needed to gather as much information as quickly 
as possible. This was normal protocol in less severe cases, but because Warner’s condition 
was deteriorating they had to rush through the process to precisely engineer his stem cell 
protocol.  
Around the second day Warner was put on an intravenous stem cell test dose, followed by 
intramuscular stem cell injections. His body was gradually prepared to respond to the cellular 
infusion, until finally, on the day of our longest conversation, he received an invasive stem 
cell-loaded spinal epidural. When I asked if he had experienced any changes since he started 
getting being treated, he responded, ‘Any changes’, he laughed, and continued: ‘I am the 
luckiest man, you can see, because this [gesturing toward the floor] was what I was before 
and now [I am here]’, he lifted his hand to indicate progress. Severe cramps in his body, 
including his neck, had receded, and he had begun sleeping for hours at a stretch: ‘Last night. 
. . . I slept two hours – [it was the] first time in two years I slept [uninterrupted for two 
hours] – and I had no [leg] cramps at all, no, no cramps at all. And, you see, I only got the 
proper spinal [epidural] today. So, visit me in three or four days and you will see [how many 
changes]!’  
He noted that in the previous two days he had been walking with a stoop, like someone with 
a severe stomachache. He compared it to walking like ‘an old stick’, bent, then said: ‘but in 
the morning I walked straight, walked normally, and my body was like a young tree and not 
an old oak. During the last twelve, fifteen to sixteen hours it changed!’ I responded, ‘It’s 
dramatically fast. Don’t you think?’ He replied, ‘Yes, yesterday in the morning I was speaking 
to my wife, and I said yesterday, “I want to die”, and this morning it is like this. I write every 
day what I feel. I am maintaining a diary’. 
Warner’s account was truly heartwarming. It was as if the stem cell cure tranquilized the 
advancing ALS. And as the aggressive symptoms slumbered Warner could at long last detect 
a vital new normality, a faint state of ‘health’ that had been dormant. Elsewhere I have 
documented the strong criticism of hESC stem cell treatment at the clinic (Bharadwaj 2013a, 
2013b, 2015). Most striking of these is the suggestion that patients, in their desperate, 
terminal state, were duped into thinking they were recovering when they were merely 
experiencing a placebo effect, and thus were victims of quackery. I checked on the placebo 
issue with Warner. Given his biomedical training, he was uniquely placed to comment on the 
role of placebo in bringing about such a sudden and dramatic change. He laughed as he 
responded: 






I know, because I am a medical doctor, so I know what a placebo effect is. And I am 
more critical as a patient and I don’t want a placebo effect, I want to be cured. So I 
was astonished after first, second injection and at night I felt like I [have] never felt 
before. I have a restless feeling so I couldn’t sleep and by morning it’s gone and I told 
them [the clinic staff]. Then I had other problems [cramps and contractions] and had 
it really bad until last night. And then it was as if someone has switched something 
[on]. That’s no placebo!  
In May 2014, exactly a year after his first treatment, I flew to Berlin to meet Warner. We 
arranged to meet at his home, with its meticulously planted garden that he had nurtured over 
the years. Warner answered the door and ushered me into the living room, where we spent 
the afternoon in the company of his wife and in-laws drinking tea and enjoying home-baked 
cake. Warner updated me on his progress. He was continuing to get stronger and could even 
work part time. His recovery narrative was interspersed with stories of setbacks, surprising 
recoveries, growing stamina, and muscular strength. He even maintained a ‘peak flow’ graph 
that painstakingly tracked his daily progress through March, April, and May. A little later we 
all walked two blocks to a neighbourhood restaurant for dinner. The evening was spent 
talking and laughing as Warner enjoyed his food, without once complaining of exhaustion.  
Later that year Warner returned to Delhi for his ‘top-up dose’, followed by another round of 
treatment in early 2015. He was initially surprised that the clinic insisted he return for 
frequent ‘top ups’, as he thought he would only have to return annually. But the clinic 
director was clear: the affliction he was countering was aggressive and needed constant stem 
cell intervention. The cultured embryonic stem cells worked as Warner had expected, and so 
did ALS, continually regenerating itself to re-establish a new pathological norm. Warner and 
his wife believe the stem cells allowed them to cheat death. He has lived two years longer 
than he would have had they allowed ALS to assert its wakeful dominance ’unchallenged.  
Conclusion 
Health is caught up in a landscape of possibilities, connections and disconnections, 
mutations and aberrations. Following a chronic and degenerative disorder, one is reminded 
that health can be an aberration, a state of pathological silence. Similarly, vigour and vitality 
can be imagined as pervasions of lethargy, a subcutaneous or hypodermal weariness, 
lassitudes that can accumulate and saturate cellular structure and erupt to the surface and 
beyond the dermal frontier. Affliction oozes, expels, and pushes forth from beyond the 
depths of frail tissue to the topography of the body. It’s a loop: outside in (micro-organisms), 
inside out (genetic), and a dialectic of outside and inside (epigenetic). The map to promised 
health is ensconced in the anatomical atlas.  






Warner’s struggle with ALS illustrates the search for defining, identifying, and naming an 
affliction. His experience captures the moment his ‘health’ or dormant illness awakened into 
a rapidly worsening affliction. His struggle to establish the ALS diagnosis and his subsequent 
search for a cure offer a fleeting glimpse into the conceptions one harbours about what the 
doctor or expert knows and how that relates to what the patient knows and experiences (Das 
2015, 219). In Warner’s case, with every stem cell insertion the affliction was seemingly 
‘cured’ to a point of dormancy that began to resemble an imagined state of health. Following 
Canguilhem (1989), structural conditions for afflictions can lurk in the corporeal depths or 
produce manifestations that interact with the external environment, which get folded into 
the intricate latticework of tissue. Stem cell insertions are tantamount to lulling ‘cured’ or 
hardened ALS to precipitate another cycle of cellular interpolation. Regenerative medicine 
shows that a chronic affliction can be ‘cured’, but we seldom see the precise separation 
between ‘cured’ as softening and ‘cured’ as the hardening of an affliction. We continue to 
mistake the state of dormancy as health. In this respect Rene Leriche’s notion of health as 
‘life lived in silence of the organs’ (quoted in Gutting 1995) cannot be understood as the 
mere absence of disease but rather as a subcutaneous or peripheral stalking, one that 
eventually breaks the misleading silence. In this respect, and rather ironically, afflictions 
remain present in their purported absence.  
An affliction is an echo. I suggest that an echo is a memory made tangible. It’s not merely a 
memory of that which has gone before, but rather it is both the tail end of what has 
occurred and what is not yet over. It’s a trace of what is ebbing out of existence and, in so 
doing, reinforcing both the memory of the event and its actual experience. The structural 
and environmental conversation continues to build, layer upon layer, the conditions for 
regenerating afflictions, cultivating cures, and new norms of ever-changing normality. As the 
extreme case of ALS shows, if there is such a thing as health then it can only be grasped in 
its absence. Health is a mere attachment to a norm that slides to new normative functioning 
stability as it interacts with regenerating afflictions. In the final analysis we have to come to 
terms with the idea that sickness and health are not antithetical but rather that they co-exist. 
Health and afflictions co-exist, hidden, silent, in deep sleep, only to rouse at a time and site 
of their choosing.  
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